ParaguayTuberculosis profile
Population  2016 6.7 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.27 (0.23–0.31) 4.1 (3.5–4.7)
Mortality (HIV+TB only) 0.044 (0.032–0.057) 0.65 (0.47–0.85)
Incidence  (includes HIV+TB) 2.8 (2.4–3.2) 42 (36–48)
Incidence (HIV+TB only) 0.27 (0.17–0.39) 4 (2.6–5.7)
Incidence (MDR/RR-TB)** 0.084 (0.036–0.13) 1.2 (0.54–1.9)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.16 (0.14–0.18) 0.72 (0.61–0.82) 0.88 (0.74–1)
Males 0.18 (0.15–0.21) 1.7 (1.5–2) 1.9 (1.6–2.2)
Total 0.34 (0.29–0.39) 2.5 (2.1–2.8) 2.8 (2.4–3.2)
TB case notifications, 2016  
Total cases notified 2 611
Total new and relapse 2 438
          - % tested with rapid diagnostics at time of diagnosis 21%
          - % with known HIV status 97%
          - % pulmonary 90%
          - % bacteriologically confirmed among pulmonary 77%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.11 (0.09–0.14)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 231 10%
          - on antiretroviral therapy 176 76%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  73
(10–140)
Estimated % of TB cases with MDR/RR-TB 0.9% (0–2.2) 15% (0–30)  
% notified tested for rifampicin resistance 27% 51% 797
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 13, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 14, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 70% 2 326
Previously treated cases, excluding relapse, registered in 2015 57% 170
HIV-positive TB cases registered in 2015 43% 182
MDR/RR-TB cases started on second-line treatment in 2014 69% 13
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 14%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
30% (27–32)
TB financing, 2017  
National TB budget (US$ millions) 23
Funding source: 14% domestic, 12% international, 75% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-18 Data: www.who.int/tb/data